FDA warns Neogen (NEOG) over contaminated “sterile” vet product tied to record horse deaths; cites insanitary manufacturing, quality-oversight failures

The documented linkage to animal deaths raises the stakes beyond a routine manufacturing citation, since it opens the company to product liability claims and potential litigation on top of the regulatory track, and the record scale of the incident makes quiet resolution less likely. The operative questions are whether the affected line is quarantined or recalled, how long remediation takes, and whether the agency escalates to enforcement action rather than accepting a corrective plan. Prior form with warning letters across the animal health and diagnostics space has tended to resolve through remediation and reinspection over quarters rather than months, with remediation costs and lost production the main financial channels rather than fines. Worth watching are the company's formal response within the standard reply window, any recall or production halt disclosures, and customer attrition in the veterinary channel, where trust in sterility claims is the core of the franchise.